Current and future therapeutic strategies in NAFLD

Current Pharmaceutical Design

Volumn 16, Issue 17, 2010, Pages 1958-1962

  de Alwis, Nimantha Mark Wilfred ^a   Day, Christopher Paul ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Fatty liver; Insulin resistance; Metabolic syndrome; Non alcoholic steatohepatitis; Obesity

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOBESITY AGENT; ANTIOXIDANT; BETAINE; EXENDIN 4; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LIRAGLUTIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; PLACEBO; PROBUCOL; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; THIAZOLIDINE DERIVATIVE; TUMOR NECROSIS FACTOR INHIBITOR; URSODEOXYCHOLIC ACID;

ANTIOXIDANT ACTIVITY; ARTICLE; BARIATRIC SURGERY; CELL PROTECTION; CLINICAL TRIAL; DIET THERAPY; DYSLIPIDEMIA; EXERCISE; FATTY LIVER; HUMAN; HYPERTENSION; INSULIN RESISTANCE; IRON DEPLETION; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WEIGHT CONTROL; WEIGHT REDUCTION; ADULT; ANIMAL; CHILD; COMPLICATION; DISEASE COURSE; PATHOPHYSIOLOGY;

ADULT; ANIMALS; CHILD; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; METABOLIC SYNDROME X; OBESITY;

EID: 77953496863     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791208901     Document Type: Article

References (73)

1. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008; 47: 1947-1954.
2. Suzuki A, Angulo P, St. Sauver J, Muto A, Okada T, Lindor K., Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am J Gastroenterol 2007; 102: 1912-1919.
3. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-210.
4. Neuschwander-Tetri BA. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis 2009; 13: 649-665.
5. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 2008; 47: 746-754.
6. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51: 121-129.
7. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-999.
8. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, NeuschwanderTetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008; 295: G987-G995.
9. Kechagias S, Ernersson A, Dahlqvist O, Lundberg P, Lindstrom T, Nystrom FH. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008; 57: 649-654.
10. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n 6/n 3 ratio in relation to hepatic steatosis in patients with nonalcoholic fatty liver disease. Clin Sci (Lond) 2004; 106: 635-643.
11. Lee S, Gura KM, Puder M. Omega-3 fatty acids and liver disease. Hepatology 2007; 45: 841-845.
12. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006; 25: 816-823.
13. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47: 711-717.
14. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004; 39: 608-616.
15. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38: 1529-1539.
16. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143-1151.
17. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42(4): 413-418.
18. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48: 1791-1798.
19. Newton JL, Jones DE, Henderson E, Kane L, Wilton K, Burt AD, et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57: 807-820.
20. Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008; 47: 1158-1166.
21. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 2006; 130: 2023-2030.
22. Frith J, Day CP, Robinson L, Elliott C, Jones DE, Newton JL. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 2010; 52: 112-116.
23. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-1112.
24. St. George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009; 50: 68-76.
25. Helmerhorst HJ, Wijndaele K, Brage S, Wareham NJ, Ekelund U. Objectively measured sedentary time may predict insulin resistance independent of moderate-and vigorous-intensity physical activity. Diabetes 2009; 58: 1776-1779.
26. Harrison S, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, nonalcoholic steatohepatitis patients. Aliment Pharmacology Ther 2004; 20: 623-628.
27. Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 2007; 52: 2512-2519.
28. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49: 80-86.
29. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003; 12: 189-192.
30. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
31. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, et al. Rimonabant reduces obesity associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats. Hepatology 2007; 46: 122-119.
32. Teixeira-Clerc F, Julien B, Grenard P, Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of Liver fibrosis. Nat Med 2006; 12: 671-676.
33. Dixon J, Bhathal P, Hughes N, O'Brien P. Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-1654.
34. Klein S, Mittendorfer B, Eagon C, Patterson B, Grant L, Feirt N, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130: 1564-1572.
35. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-1654.
36. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-540.
37. Adachi M, Osawa Y, Uchinami H, Kitamura T, Accili D, Brenner D. The forhead transcription factor foxo1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology 2007; 132: 1434-1446.
38. Juurinen L, Tiikkainen M, Hakkinen A, Hakkarainen A, Yki-Jarvinen H. Effects if insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diebetes. Am J Physiol Endocrinol Metab 2006; 292: E829-E835.
39. Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 2010; 33: 284-286.
40. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomised control trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-1090.
41. Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K, et al. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-860.
42. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-1940.
43. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307.
44. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-1184.
45. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-110.
46. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-453.
47. Sanyal AJ. A randomized controlled trial of pioglitazone or Vitamin E for nonalcoholic steatohepatitis (PIVENS). Hepatology 2009; 50 (Suppl): 1A.
48. Singh S, Loke Y, Furberg C. Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. J Am Med Ass 2007; 98: 1189-1195.
49. Lincoff M, Wolski K, Nicholls S, Nissen S. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. J Am Med Ass 2007; 298: 1180-1188.
50. Lutchman G, Modi A, Kleiner D, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-429.
51. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006; 26: 1015-1017.
52. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 1286-1296.
53. Laurin J, Lindor K, Crippin J, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-1467.
54. Browning J. Statins and hepatic steatosis: Perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-471.
55. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45: 1375-1381.
56. Oben JA, Roskams T, Yang S, Lin H, Sinelli N, Li Z, Torbenson M, et al. Norepinephrine induces hepatic fibrosis in leptin deficient ob/ob mice. Biochem Biophys Res Commun 2003; 308: 284-292.
57. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensinogen II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225.
58. Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007; 46: 1331-1336.
59. Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, et al. Probucol in the treatment of nonalcoholic steatohepatitis: a double blind randomixed controlled study. J Hepatol 2003; 38: 414-418.
60. Abdelmalek M, Angulo P, Jorgensen R, Sylvestre P, Lindor K. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study. Am J Gastroenterology 2001; 96: 2711-2717.
61. Facchini F, Hua N, Stoohs R. Effect of Iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-939.
62. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490.
63. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48): 119-128.
64. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-1543.
65. Adams LA, Zein C, Angulo P, Lindor K. A pilot trial of pentoxyfylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 2365-2368
66. Satapathy S, Sakhuja P, Malhotra V, Sharma B, Sarin S. Beneficial effects of pentoxifyllin on hepatic steatosis,fibrosis and necroinflammation in patients with non alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 634-638.
67. Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, et al. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 2008; 57: 655-663.
68. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350.
69. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith R, et al. Chemical chaperones reduce er stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-1140.
70. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of Non Alcoholic stetaohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-778.
71. Witek RP, Stone WC, Karaca FG, Syn W-K, Pereira TA, Agboola KM, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009; 50: 1421-1430.
72. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. 2001: 7(4): 363-373.
73. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801.